Nasdaq:VERA

<!-- Name:DistributionId Value:8741398 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value: -->…

New analysis of Phase 2a JANUS clinical trial showed atacicept reduced immune complex levels in patients with IgA nephropathy (IgAN)Atacicept is the first therapeutic to show reduction in all of the three first hits of IgAN pathogenesis…